药物基本信息
通用名：阿替普酶
适应症：用于治疗急性心肌梗死和肺栓塞；用于治疗急性缺血性脑卒中、深静脉血栓及其他血管疾病。
市场需求
阿替普酶（t-PA）在我国《急性缺血性脑卒中诊治指南》、《重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中中国专家共识》以及美国心脏协会和美国卒中协会（AHA/ASA）《急性缺血性脑卒中患者的早期处理指南》中均获推荐用于急性期的溶栓治疗。阿替普酶（t-PA）是一种生理性溶栓药，可以防止血栓形成和增大。它是治疗冠脉血栓、肺血栓和急性缺血性脑卒中最常用的溶栓药。至今仍然是FDA唯一批准用于缺血性脑卒中的溶栓药物，被认为是脑卒中溶栓药物的“金标准”。
The basic information of drug
common name: Alteplase
Indications: Treatment of acute myocardial infarction and pulmonary embolism; treatment of acute ischemic stroke, deep vein thrombosis and other vascular disease.
Market demand
t-PA is recommended for acute thrombolytic therapy in the "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke ", "Expert consensus on the treatment of ischemic stroke by intravenous thrombolytic therapy with recombinant tissue plasminogen activator" of China and "Guidelines for Early Treatment of Patients with Acute Ischemic Stroke" of American Heart Association and American Stroke Association (AHA / ASA). t-PA is a physiological thrombolytic agent that prevents thrombosis and increases. It is the most commonly used thrombolytic agent for the treatment of coronary thrombosis, pulmonary thrombosis and acute ischemic stroke. It is still the only FDA approved for ischemic stroke thrombolytic drugs and is considered to be thrombolytic drugs "gold standard."
（阿替普酶作用机制，图片来源医博士）
